Primary regulatory
FDA response to NMN DSHEA exclusion question
FDA determination that NMN (nicotinamide mononucleotide) is excluded from the dietary supplement definition under DSHEA because it was first authorized for investigation as a new drug. This triggered marketplace disruption for NMN supplements.
U.S. Food and Drug AdministrationPublished 2022-11-02Accessed 2026-07-01
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-nmn-dshea-determination-2022
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.